In Re: Zofran (Ondansetron)Products Liability Litigation

Track this case

Case Number:

1:15-md-02657

Court:

Massachusetts

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Multi-district Litigation

Judge:

F. Dennis Saylor, IV

Firms

Companies

Glenmark Pharmaceuticals Ltd.

Sectors & Industries:

Healthcare
- Generic

March 18, 2020
First Zofran Bellwether Delayed Indefinitely Due To COVID-19

The first bellwether in multidistrict litigation over whether GlaxoSmithKline's anti-nausea medication Zofran causes birth defects has been postponed indefinitely amid the coronavirus pandemic, and a federal judge said Wednesday there is no timetable for when the long-running case may finally go to trial.
February 20, 2020
No Sanctions For GSK, But Both Sides Told To 'Dial It Back'

GlaxoSmithKline will not face sanctions for a call to the U.S. Food and Drug Administration tied to multidistrict litigation over whether its anti-nausea medication Zofran causes birth defects, a Boston federal judge ruled Thursday, but he admonished lawyers on both sides to "dial ... back" their rhetoric.
February 19, 2020
Glaxo Says FDA Call About Zofran Suits Not 'Covert Lobbying'

GlaxoSmithKline attorneys have told a Massachusetts federal judge that a 30-minute phone call with the U.S. Food and Drug Administration about multidistrict litigation alleging its anti-nausea medication Zofran causes birth defects wasn't "covert lobbying" and doesn't warrant sanctions.
February 05, 2020
Zofran Plaintiffs Say GSK Hid FDA Lobbying From Discovery

Citing what GlaxoSmithKline attorneys have called "some crazy conspiracy theory," plaintiffs claimed Wednesday that GSK hid from discovery its efforts to lobby the U.S. Food and Drug Administration about the multidistrict litigation case alleging the company's anti-nausea medication Zofran caused birth defects.
January 15, 2020
GSK Seeks To Forgo Trial In First Zofran MDL Bellwether

GlaxoSmithKline argued in court Wednesday to prevail on simply a paper record in the first trial in a multidistrict case over whether the company's anti-nausea medication Zofran caused birth defects, claiming a California mother cannot show she wouldn't have taken Zofran anyway, even with a birth defect warning.
October 24, 2019
GSK Loses Bid To End 53 Zofran Birth Defects Cases

GlaxoSmithKline has largely lost its bid to end 58 cases in a consolidated suit claiming its anti-nausea medication Zofran caused birth defects when taken by pregnant women, as a Massachusetts federal judge said enough conflicting evidence remains to keep 53 of the suits alive.
October 23, 2019
Birth Defect Report Trimmed By Judge In Zofran MDL

GlaxoSmithKline convinced a Massachusetts federal judge to slice off part of an expert report by a doctor who testified anti-nausea drug Zofran can cause birth defects when taken by pregnant women.
July 19, 2019
GSK Calls For Preemption Ruling In Zofran Birth Defect MDL

GlaxoSmithKline has renewed its bid to end multidistrict litigation in Massachusetts federal court over claims it didn't warn customers about alleged birth defects resulting from its anti-nausea medication, saying a recent Supreme Court ruling opens the way for the judge to rule the claims are preempted by federal law.
July 10, 2019
GSK Gets 2nd Chance To Argue Preemption In Zofran MDL

A Massachusetts federal judge on Wednesday said GlaxoSmithKline will get another chance to argue that claims its anti-nausea drug Zofran caused birth defects are federally preempted, adding he will seek guidance from the FDA after a landmark high court ruling put the preemption question in his hands.
June 11, 2019
GSK Seeks Ax Of Zofran Birth Defect Claims

GlaxoSmithKline on Tuesday asked a Massachusetts federal judge to toss certain claims in multidistrict litigation alleging that its anti-nausea drug Zofran caused birth defects, saying that the patients hadn't shown the drug caused some of the purported defects.